About: Feasibility and safety of peripheral blood stem cell transplantation from unrelated donors: results of a single-center study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Feasibility and safety of peripheral blood stem cell transplantation from unrelated donors: results of a single-center study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Feasibility and safety of peripheral blood stem cell transplantation from unrelated donors: results of a single-center study
Creator	Basara, N Bischoff, M Guenzelmann, S Kiehl, M Kirsten, D Lentini, G Roemer, E Fauser, A Blau, I
source	PMC
abstract	We compared the outcomes in patients receiving unrelated peripheral blood stem cell transplants (PBSCT) with those receiving bone marrow transplants (BMT) in a matched pair analysis. Seventy-four patients with hematological malignancies with HLA-matched (77%) and mismatched (23%) donors were analyzed in this study. Thirty-four patients (45%) were considered as high risk patients. Sixty-eight patients received standard conditioning regimens with Bu/Cy or TBI/Cy. Six patients received an intensified conditioning regimen with the addition of etoposide, thiotepa or melphalan. GVHD prophylaxis consisted of prednisolone, cyclosporine and methotrexate. Groups were matched for patient, donor, transplant characteristics and HLA compatibility. Peripheral blood stem cell collection led to the collection of a higher number of CD34(+) and CD3(+) cells in comparison to bone marrow collection. Leukocyte engraftment in the PBSCT group occurred in 14 days (median; range 6–26 days) and in the BMT group in 19 days (range 9–29 days; P < 0.02). The time of platelet engraftment did not differ significantly. The incidence of grades II–lV acute GVHD in the group of HLA-identical patients was 35% in the PBSCT group and 25% in the BMT group (P < 0.33, log-rank). However, there was a significant difference (P < 0.05, log-rank) in incidence and time to onset of acute GVHD II–IV comparing all patients, including the 17 mismatched transplants. Disease-free survival was 51% (19 patients) with a median of 352 days and 59% (21 patients) with a median of 760 days for PBSC and BMT transplants, respectively. In conclusion, our results indicate that allogeneic PBSCT led to significantly faster leukocyte engraftment but is associated with a higher incidence and more rapid onset of severe acute GVHD comparing all patients, including the 17 mismatched transplants. However, the incidence of severe acute GVHD in HLA-identical patients was not different between the PBSCT and BMT groups. Bone Marrow Transplantation (2001) 27, 27–33.
has issue date	2001-01-15(xsd:dateTime)
bibo:doi	10.1038/sj.bmt.1702734
bibo:pmid	11244435
has license	no-cc
sha1sum (hex)	c8ab2c19781e7d41e7ba490524a2c06c112f3a6d
schema:url	https://doi.org/10.1038/sj.bmt.1702734
resource representing a document's title	Feasibility and safety of peripheral blood stem cell transplantation from unrelated donors: results of a single-center study
has PubMed Central identifier	PMC7091592
has PubMed identifier	11244435
schema:publication	Bone Marrow Transplant
resource representing a document's body	covid:c8ab2c19781e7d41e7ba490524a2c06c112f3a6d#body_text
is schema:about of	named entity 'high risk' named entity 'time' named entity 'median' named entity 'GVHD' named entity 'stem cell' named entity 'transplant' named entity 'cyclosporine' named entity 'comparing' named entity 'Six' named entity 'STUDY' named entity 'PREDNISOLONE' named entity 'COMPARISON' named entity 'PERIPHERAL BLOOD STEM CELL' named entity 'GRADES' named entity 'TIME' named entity 'DID' named entity 'PLATELET ENGRAFTMENT' named entity 'TRANSPLANTS' named entity '0.02' named entity 'ACUTE GVHD' named entity 'BONE MARROW COLLECTION' named entity 'COMPARING' named entity 'SIXTY-EIGHT' named entity '0.33' named entity 'STANDARD' named entity 'PBSCT' named entity 'THIRTY' named entity 'CONCLUSION' named entity 'GVHD PROPHYLAXIS' covid:arg/c8ab2c19781e7d41e7ba490524a2c06c112f3a6d named entity 'range' named entity 'patients' named entity 'prednisolone' named entity 'PBSC' named entity 'severe' named entity 'acute' named entity 'patients' named entity 'transplants' named entity 'study' named entity 'severe' named entity 'cells' named entity '2001' named entity 'rapid' named entity 'bone marrow' named entity 'leukocyte' named entity 'platelet' named entity 'HLA' named entity 'GVHD' named entity 'hematological malignancies' named entity 'CD34' named entity 'peripheral blood stem cell' named entity 'Bone Marrow Transplantation' named entity 'peripheral blood stem cell transplantation' named entity 'donor lymphocyte infusion' named entity 'allogeneic' named entity 'ANC' named entity 'bacterial pneumonia' named entity 'hypocalcemia' named entity 'leukocyte' named entity 'G-CSF' named entity 'flow cytometry' named entity 'mycophenolate mofetil' named entity 'PBSC' named entity 'Thousand Oaks' named entity 'PCR' named entity 'nucleated cells' named entity 'GVHD' named entity 'PBSC' named entity 'refractory' named entity 'prophylaxis' named entity 'severe infections' named entity 'Kaplan-Meier method' named entity 'G-CSF'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software